Back

Prognostic value of hyperkalemia and mineralocorticoid receptor antagonist use in heart failure: a national registry study

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Mineralocorticoid receptor antagonists: from trials to real life Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Kristian Berge

Akershus University Hospital - AHUS, Nordbyhagen (Norway)

6 More presentations in this session

Presentation thumbnail
Temporal trends in mineralocorticoid receptor antagonist use among patients with heart failure in a community-based cohort
Doctor A. Ambrosy (San Francisco, US)
Abstract Video
Presentation thumbnail
Finerenone: from evidence to clinical practice. Data from the finerlife registry (finerenone in real life)
Mr A. Hernandez Concepcion (Palmas de Gran Canaria, Las, ES)
Abstract Video
Presentation thumbnail
SENEKA: a randomized clinical trial to optimize RAASi therapy using sodium zirconium cyclosilicate in elderly patients with heart failure and chronic kidney disease at risk of hyperkalemia
Doctor C. Bonanad Lozano (Valencia, ES)
Abstract Video
Presentation thumbnail
Mineralocorticoid receptor antagonists in heart failure: real-world uptake, dose titration, hyperkalaemia trends, and potassium binder use
Doctor T. Furlan (Trbovlje, SI)
Abstract Video
Presentation thumbnail
Real-life indications of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction
Doctor G. Antonelli (Rozzano, IT)
Abstract Video

Access the full session

Session thumbnail
Mineralocorticoid receptor antagonists: from trials to real life

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Hyperkalemia events in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan or sodium-glucose transport protein 2 inhibitors: a single-center experience
thumbnail
Congress Presentation
Hypokalemia during hospitalization: a strong predictor of mortality in acute heart failure
thumbnail
Congress Presentation
Hyperkalemia, clinical outcomes, and mineralocorticoid receptor antagonist in heart failure: insights from the REVIEW-HF registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources